Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
Eli Lilly's weekly insulin, Onswik, received FDA approval, offering patients over 300 fewer injections annually. The drug showed a 1.34% reduction in A1C levels in trials, compared to 1.26% for Novo's Tresiba. Lilly plans to launch Onswik in the U.S. soon, intensifying competition with Novo, which recently got approval for its own weekly insulin, Awiqli.
How this was made
The 30-second read
Why it matters
The approval expands Lilly's diabetes portfolio and could capture market share from Novo, influencing insulin pricing dynamics.
Market read
A new FDA‑approved weekly insulin is a significant product launch for a major pharma, likely moving the stock and affecting the diabetes therapeutic space.
What to watch
Potential reimbursement challenges and manufacturing scale-up risks.
Background
Eli Lilly's Onswik joins a small set of once‑weekly insulins after FDA clearance, following Novo's Awiqli approval.
Ticker impact
Eli Lilly received FDA approval for its weekly insulin Onswik, a new product launch.
Potential upside of 5-10% in the near term.
Regulatory clearance for a novel weekly insulin is a material catalyst for a large‑cap pharma.
Market effects
Strengthens the diabetes/insulin segment and may pressure competitors.
U.S. market sees a new weekly insulin option; global markets watch for rollout.
Adds competitive pressure on Novo Nordisk globally.
Counterpoint
Market may have already priced in the approval; upside limited.
Key entities
- CompanyEli Lilly
Developer of the newly approved weekly insulin Onswik.
- CompanyNovo Nordisk
Competitor with its own weekly insulin Awiqli.
